WASHINGTON, 28 October 2026 — The United States health department said on Wednesday it will temporarily allow licensed pharmacies and physicians to compound six unapproved peptide ingredients, while regulators decide whether to formally permit their use, in a policy that has divided health officials and drawn scrutiny over how it was decided.
Illustration: A pharmacist in a compounding pharmacy laboratory preparing medicines with vials and lab equipment.
What Happened
The interim policy, published in the Federal Register, was reported by Reuters on 28 October 2026. It covers six peptides: BPC-157 and TB-500, often taken together in a combination popularly known as the "Wolverine stack", as well as epitalon for insomnia, KPV for wound healing and inflammatory conditions, MOTS-c for obesity and osteoporosis, and Semax for migraines and chronic pain.
Under the policy, the Department of Health and Human Services (HHS) said it would not take enforcement action against compounders using those ingredients, provided they meet requirements on ingredient quality, manufacturing standards, safety reporting, labelling and patient-specific prescriptions. The decision follows a recommendation from a Food and Drug Administration (FDA) advisory committee in July 2026 to allow all six peptides in compounding, Reuters reported.
The move is significant because compounded drugs are not FDA-approved, meaning the agency does not review their safety, effectiveness or quality before they are marketed. The FDA has some oversight of compounding facilities together with state pharmacy boards, but a compounded product does not go through the same approval process as a licensed medicine. HHS said the policy would discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients, and would improve patient access.
US Health Secretary Robert F. Kennedy Jr. has supported broader access to peptides, calling himself a "big fan" of the treatments, and has argued that Americans were importing unsafe products. According to reporting by the Associated Press, relayed by The Guardian, six people familiar with the process said most FDA scientific staff opposed the plan and had limited input in drafting it, while the effort was driven largely by HHS. Those sources spoke anonymously because they were discussing confidential deliberations. Reuters separately reported that the FDA's staff had recommended against allowing the peptides, and that several advisory panel members had ties to peptide-selling businesses or clinics, although HHS said all members cleared standard ethics checks.
Illustration: Small medicine vials and syringes on a laboratory bench in a pharmacy.
Background
Peptides are short chains of amino acids, the building blocks of proteins. Some occur naturally in the body, while others are made in laboratories for research. Over the past year, a set of unapproved peptides has boomed in popularity in the United States, driven by endorsements from wellness influencers, for uses ranging from anti-ageing to muscle recovery and tissue repair.
That boom created a regulatory grey zone. Peptides sold as "research-use-only" products were widely available online, often from foreign suppliers, without prescriptions, quality controls or safety testing. At the same time, some patients and practitioners argued that licensed compounding pharmacies, which prepare customised medicines for individual patients, should be allowed to supply the same substances under professional supervision instead. The FDA's compounding rules are meant to draw a line between legitimate customised preparation and unapproved mass manufacturing, but the rapid growth of the peptide market has strained that line.
The advisory committee's July recommendation to allow all six peptides in compounding was therefore a turning point. Advisory committees advise the FDA, but their recommendations are not binding, and agency staff can disagree with them. In this case, Reuters reported that staff recommended against the move, setting up the unusual situation in which the health department's enforcement-discretion policy effectively overrode the caution of the agency's own scientists, at least temporarily.
The controversy also touches a wider debate about how the United States regulates wellness products. Supporters of wider access argue that adults should be able to obtain substances they believe help them, especially when the alternative is an unregulated online market. Critics argue that popularity on social media is not evidence of safety or effectiveness, and that allowing compounding without FDA approval risks giving unproven products an appearance of legitimacy they have not earned.
Why It Matters
First, the policy changes what patients can legally obtain from a pharmacy, even though none of the six peptides has been proven safe or effective through FDA approval. That distinction matters: a compounded peptide may now be supplied under professional supervision, but it still has not passed the clinical trials and agency review required of licensed medicines. Patients should understand that difference, and this article is general news reporting, not medical advice; anyone considering such a product should discuss it with a qualified clinician.
Second, the decision raises questions about how scientific advice is weighed inside the health department. When an advisory committee, agency staff and department leadership point in different directions, the outcome reveals where real decision-making power sits. If staff concerns about safety and evidence are set aside, other regulated industries and patient groups will watch closely to see whether the same approach is used elsewhere.
Third, the policy could reshape the peptide market itself. By bringing supply into licensed pharmacies with quality, labelling and safety-reporting requirements, HHS hopes to squeeze out riskier foreign research-use-only products. Whether that happens depends on enforcement in practice: requirements on paper only protect patients if compounders follow them and regulators check.
Illustration: A large government health agency building in Washington DC with columns and flags.
What Happens Next
The policy is temporary. Regulators must still decide whether to formally permit the six peptides in compounded medicines, and that decision will be watched for the evidence it cites and the conditions it imposes. Public and professional reaction in the coming weeks, including from medical associations, pharmacy boards and patient groups, may shape whether the interim approach is extended, narrowed or reversed.
Scrutiny of the decision-making process is also likely to continue. The reported disagreement between FDA scientific staff and HHS leadership, and the reported ties between some advisory panel members and peptide-selling businesses, have already drawn attention, and further reporting may clarify who decided what and on what evidence. HHS has said ethics checks were cleared; critics may press for more detail.
For patients, the practical message is caution. The peptides remain unapproved, their benefits for the uses promoted online remain unproven, and compounded products can vary in quality even under the new requirements. Anyone offered one of the six peptides should ask what evidence supports its use, what risks are known, and whether a licensed, approved alternative exists, and should seek advice from a clinician rather than relying on influencer claims.
Sponsored: explore today's featured sponsored offers
FAQ
Which peptides does the new US policy cover?
Six: BPC-157 and TB-500, often combined as the "Wolverine stack", plus epitalon, KPV, MOTS-c and Semax, for uses including tissue repair, insomnia, wound healing, obesity, osteoporosis, migraines and chronic pain, as described by Reuters.
Does this mean the peptides are now FDA-approved?
No. Compounded drugs are not FDA-approved, and the agency does not review their safety, effectiveness or quality before marketing. The policy only means HHS will not take enforcement action against qualifying compounders while a formal decision is pending.
Why is the policy controversial?
Reuters reported that FDA staff recommended against allowing the peptides, and Associated Press reporting relayed by The Guardian said most FDA scientific staff opposed the plan and had limited input, while HHS drove the effort. HHS said advisory members cleared standard ethics checks.
What conditions must compounders meet?
According to HHS, compounders must meet requirements on ingredient quality, manufacturing standards, safety reporting, labelling and patient-specific prescriptions to qualify for the enforcement discretion.
What should patients do?
This article is general news, not medical advice. Patients should discuss any peptide product with a qualified clinician, ask about evidence and risks, and check whether an approved alternative exists, rather than relying on social-media promotion.
Sources
- Reuters via SRN News, "US health department to allow temporary sale of some unapproved peptides", 28 October 2026
- Reuters via Duke FM, "US Health Secretary Kennedy opens access to some unapproved peptides", 28 October 2026
- Associated Press reporting relayed by The Guardian, on FDA scientific staff opposition to the peptide plan, 28 October 2026
Comments
Post a Comment